JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Day One Biopharmaceuticals Inc

Fechado

SetorSaúde

6.88 2.08

Visão Geral

Variação de preço das ações

24h

Atual

Mín

6.65

Máximo

7.03

Indicadores-chave

By Trading Economics

Rendimento

30M

-36M

Vendas

1.6M

31M

Margem de lucro

-117.018

Funcionários

181

EBITDA

24M

-40M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+304.21% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-71M

733M

Abertura anterior

4.8

Fecho anterior

6.88

Sentimento de Notícias

By Acuity

50%

50%

175 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 21:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 de ago. de 2025, 21:21 UTC

Ganhos
Grandes Movimentos do Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 de ago. de 2025, 20:45 UTC

Ganhos

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 de ago. de 2025, 21:30 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 21:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 de ago. de 2025, 21:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 20:25 UTC

Conversa de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss $938M >RIG

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss/Shr $1.06 >RIG

4 de ago. de 2025, 20:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 de ago. de 2025, 20:15 UTC

Ganhos

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 de ago. de 2025, 20:13 UTC

Ganhos

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 de ago. de 2025, 20:09 UTC

Ganhos

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 de ago. de 2025, 20:06 UTC

Ganhos

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 de ago. de 2025, 19:41 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 de ago. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 de ago. de 2025, 19:07 UTC

Conversa de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 de ago. de 2025, 18:27 UTC

Conversa de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparação entre Pares

Variação de preço

Day One Biopharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

304.21% parte superior

Previsão para 12 meses

Média 26.88 USD  304.21%

Máximo 36 USD

Mínimo 18 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.26 / 7.47Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

175 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.